The Hindu·3 min read·medium
CDSCO clears recombinant live attenuated dengue vaccine for ages 4 to 60 years
B
Bindu Shajan Perappadan
✦AI Summary
India's Central Drugs Standard Control Organisation has approved the Qdenga dengue vaccine for individuals aged 4 to 60. Developed by Takeda, the vaccine uses recombinant DNA technology and has already received regulatory approval in 42 other countries.
India has approved its first dengue vaccine , with the Central Drugs Standard Control Organisation (CDSCO) granting marketing authorisation for the Dengue Tetravalent Vaccine (Live, Attenuated) – Qdenga. Manufactured by Takeda GmbH, Germany, the vaccine will be imported by Takeda Biopharmaceuticals India Pvt. Ltd.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in